A 124,387-Person Swedish Study Ranked Family Cancer Count Above a Relative's Age at Diagnosis

September 3, 2026 · Science · Gut Health

What the Study Reported

How many relatives had colorectal cancer predicted risk better than how young one of them was when diagnosed. That is the finding from a Swedish registry study published in Gastroenterology on September 3, 2026 by researchers at Karolinska Institutet, under the digital object identifier (DOI) 10.1053/j.gastro.2026.08.029.

The dataset is large enough to answer the question it asks. The team followed 124,387 people in Sweden with inflammatory bowel disease (IBD) between 1996 and 2023, alongside just over 1.2 million matched people from the general population, for a median of 11 years. Over that period 1,882 of the people with IBD developed colorectal cancer.

Two comparisons carry the result. People with IBD who had two or more first-degree relatives with colorectal cancer were about 2.6 times as likely to develop it as people with IBD and no family history. For those with a single relative diagnosed before age 50, the increase was just under 50 percent. Åsa Everhov, quoted in the Karolinska Institutet announcement, said "the number of cancer cases in the family may be a more important risk marker".

Why the Count of Relatives Beat the Early Diagnosis

Family history is usually treated as a single yes-or-no box on an intake form. Where guidelines refine it, the refinement is typically the age of the youngest affected relative, on the reasoning that early-onset cancer signals stronger inherited risk. That reasoning still holds. What this study adds is that a second detail on the same form, the number of relatives affected, tracked risk more closely in this population.

The size of the gap makes it practical. About 2.6 times against just under 50 percent higher is a wide separation between two markers. Both were also measured in the same cohort over the same follow-up, which removes most of the reasons two risk estimates usually disagree. Swedish national registers also capture cancer diagnoses and family links across the whole population, so the family history here comes from records rather than patient recall.

That last point is a genuine strength worth naming. Self-reported family history is known to be incomplete, particularly for relatives who died before the person reporting was old enough to remember. A register-linked count avoids that, which is why a Nordic dataset can answer a question of this shape that a clinic-based cohort cannot.

The Finding About Absolute Risk

Karolinska Institutet reports that a family history of colorectal cancer carried roughly the same absolute risk regardless of whether the person had IBD. Two risk factors that add are handled differently from two that multiply, and the distinction changes how a clinician reads a chart.

For a person with IBD, it means family history is not amplified by the bowel disease into something larger than it would be in anyone else. For the general population, it means the same count of affected relatives carries a comparable weight without IBD in the picture. The practical consequence is that this information transfers: a family cancer count is worth collecting and worth stating to a doctor whether or not IBD is part of the history.

One caution belongs with it. Absolute risk figures by group were not published in the announcement, so the phrase describes a comparison rather than a number a reader can apply. The paper itself sits behind a subscription at Gastroenterology, where those figures will be stated.

What This Changes for Screening and Testing Decisions

The most useful item in this study costs nothing and is sold by nobody. It is a count of first-degree relatives with colorectal cancer, along with the age each was diagnosed. That count outperformed a good deal of what the testing market sells for risk assessment, and collecting it takes one conversation at a family gathering.

That matters because of where the money currently goes. Multi-cancer early detection blood tests and consumer gut panels are marketed heavily to people worried about colorectal cancer, and they answer a different question. A detection test asks whether something is present now. A risk marker asks what the coming decades look like, which changes how often a person should be scoped rather than whether they have cancer today. Our briefing on the Galleri regulatory review covers where that detection evidence currently stands, and our briefing on colorectal screening and mortality covers what screening itself has been shown to do.

For anyone with IBD comparing consumer testing options, the gastroenterology relationship ranks first. Surveillance colonoscopy in IBD is a guideline-driven schedule that a subscription panel does not replace and cannot inform. Our guide to how doctors test gut health sets out which of these tests clinicians actually use, and the gut health hub collects the rest. Bring the family count to the gastroenterologist managing the case, and let the surveillance interval be their call.

What Would Change This Read

Replication outside the Nordic registers would matter most. Sweden's population registers are unusual in their completeness. A finding built on them needs testing where family history is recorded less thoroughly, to show the ranking reflects biology rather than data quality.

Publication of the hazard ratios and their intervals would let a reader judge precision. About 2.6 times is a point estimate, and the width of the interval around it decides whether the ranking against early-onset family history is firm or provisional.

A guideline body acting on it would change what happens in clinic. The authors raise the question of whether the number of affected relatives should carry more weight in risk assessment. Until a surveillance guideline adopts that, the finding informs a conversation rather than a schedule.

Related Coverage

Our briefing on colorectal screening and mortality covers what the screening tests themselves have been shown to achieve. The briefing on Galleri reaching employer health plans covers how multi-cancer detection is being distributed while its evidence is still under review. Read together with this study, they mark out the three separate questions a reader tends to collapse into one: what raises risk, what detects disease, and what actually lowers deaths. The gut health hub and the platforms hub collect the reviews those decisions start from.

Sources

• Karolinska Institutet, "Family cancer burden predicts risk in patients with inflammatory bowel disease," news.ki.se (accessed September 3, 2026). Source of the 124,387 people with IBD in Sweden between 1996 and 2023, the comparison group of just over 1.2 million people from the general population, the median follow-up of 11 years, the 1,882 colorectal cancers among people with IBD, the approximately 2.6 times higher likelihood with two or more affected first-degree relatives, the just under 50 percent higher risk with one relative diagnosed before age 50, the finding of roughly equal absolute risk with and without IBD, the quoted remark from Åsa Everhov, and the disclosure that authors report research collaborations, grants or other assignments with pharmaceutical companies.
• MedicalXpress, "Family cancer burden predicts risk in patients with inflammatory bowel disease," September 3, 2026, medicalxpress.com (accessed September 3, 2026). Source of the journal, the paper title, the DOI 10.1053/j.gastro.2026.08.029, and the authors' question about whether future screening guidelines should place greater emphasis on the number of cancer cases in a patient's family.
• The paper's page at Gastroenterology requires a subscription. Hazard ratios, confidence intervals and absolute risk percentages by group are not published in either source above, and none appear on this page.